CRISPR CLINICAL TRIALS

Medicine is changing.

New CRISPR gene editing clinical studies are rapidly emerging and we think a comprehensive overview is valuable to help keep track of them all.

CRISPR is the hot new rapidly rising gene editing tool but we also include clinical trials of other gene editing modalities like the Zinc Finger Nucleases, TALENs, MegaTALS, MegaNucleases and any new variants that will be out there in the future. We will keep updating our overview.

Check already now the world's-first clinical trial for a CRISPR-Cas3 phage therapy for treatment of urinary tract infections, developed by Locus BioSciences and get all the details about their unique technology from this interview with VP, Business Development, Joseph Nixon.

The clinical trials are arranged in the following areas: Antibacterials, Blood, Cancer, Eye and Metabolic disorders.

CRISPR-Cas | TALENS | ZFN

Antibacterial

Indicator
IND Enabling
Phase I
Phase II
Phase III

Blood

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Human Immunodeficiency Virus Infection, HIV, (NCT03164135)
Sponsors:

Affiliated Hospital to Academy of Military Medical Sciences

IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Cancer

Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
B Cell Malignancy, NHL, (NCT03166878)
Sponsors:

Chinese PLA General Hospital

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastro-Intestinal Cancer, GI, (NCT04426669)
Sponsors:

Intima Bioscience, Inc.

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Solid Tumor Adult, (NCT03545815)
Sponsors:

Chinese PLA General Hospital

Indicator
IND Enabling
Phase I
Phase II
Phase III
Nasopharyngeal Carcinoma, (NCT03044743)
Sponsors:

Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor Adult, (NCT03747965)
Sponsors:

Chinese PLA General Hospital

Indicator
IND Enabling
Phase I
Phase II
Phase III

Eye

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Metabolic disorder

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine